Alnylam to Contribute IP to Tropical Disease Research Effort | GenomeWeb

NEW YORK (GenomeWeb News) – Alnylam today said that it has joined GlaxoSmithKline in contributing more than 1,500 issued or pending patents covering RNA interference technology to a patent pool for neglected tropical diseases.

The patent pool was established by London-based GlaxoSmithKline earlier this year to aid in the discovery and development of new medicines for treating 16 neglected tropical diseases, as defined by the US Food and Drug Administration, in the world's least developed countries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.